BioSpace News Archive

Bionano Genomics, Inc., announced significant upgrades to its pipeline for analysis of optical genome mapping data in its VIA™ software for applications in constitutional genetic disease.

Medalogix and Amedisys announced an expanded partnership with the implementation of Medalogix Pulse for Home Health patients.

Heranova Lifesciences Holding Ltd. announced the successful completion of a USD 13.5 million seed and seed+ financing to develop and offer integrated Women’s Health solutions worldwide.

SeaStar Medical Holding Corporation announces enrollment of 12 subjects in the NEUTRALIZE-AKI pivotal clinical trial evaluating the safety and efficacy of its patented, first-in-class, cell-directed Selective Cytopheretic Device extracorporeal therapy in critically ill adults with acute kidney injury requiring continuous kidney replacement therapy.

NeuroBo Pharmaceuticals, Inc. announced that it has submitted an Investigational New Drug application to the U.S. Food and Drug Administration.

Sight Sciences, Inc. announced by five Medicare Administrative Contractors to withdraw their final local coverage determinations for Micro-Invasive Glaucoma Surgery that were scheduled to take effect on January 29, 2024.

Hi-Tech Pharmaceuticals, a leading manufacturer of cutting-edge dietary supplements and weight management supplements, is proud to announce the launch of its latest product, SLIMAGLUTIDE®.

HR Pharmaceuticals, Inc. announced that they have entered into an Exclusive Commercial Agreement with Poiesis Medical LLC, under which HRP will license Poiesis’s Dual Balloon Catheter.

Trevena, Inc. announced that it has closed its previously announced offering for the issuance and sale of 2,779,906 shares of common stock of Trevena and warrants to purchase up to an aggregate of 2,779,906 shares of common stock of Trevena, at a purchase price of $0.70 per share and associated warrant in a private placement, for gross proceeds to the Company of approximately $1.946 million.

Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ Pulsed Field Ablation System* as a first-line treatment for persistent atrial fibrillation, the only trial to study the use of PFA as frontline therapy in patients with this form of AF.